RARA CRAFT DATABASE for FDA Medical Devices
510(k)K261853

FDA DEVICE FACTS

Gepotidacin GEP 10 µg

Liofilchem, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

PCCP: Authorized
DECISION DATEJuly 23, 2026PRODUCT CODEJTN

Indications for use

Gepotidacin GEP 10 μg is an in vitro semi-quantitative method for antimicrobial susceptibility of clinical isolates tested on agar media using overnight incubation. The Gepotidacin GEP 10 μg is intended to determine susceptibility of Enterobacterales, Enterococcus faecalis, and Staphylococcus saprophyticus to gepotidacin, as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). Gepotidacin at a concentration of 10 μg should be interpreted at 16-18 hours of incubation. The Gepotidacin GEP 10 μg demonstrated acceptable performance with the following organisms: Enterobacterales (Citrobacter freundii, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Providencia rettgeri) Enterococcus faecalis Staphylococcus saprophyticus

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 11, 2026